Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amerisource Faces Government Source: CEO Disputes Report Of Inquiry

Executive Summary

An investigation of AmerisourceBergen's role in facilitating drug diversion appears to focus on an institutional pharmacy that Amerisource dropped as a client in 2000, CEO David Yost said

You may also be interested in...



Rx Wholesalers Responding To Subpoenas On Deals With “Secondary” Market

AmerisourceBergen, Cardinal Health and McKesson are responding to subpoenas from the New York Attorney General's office regarding their use of "secondary" wholesalers as a source of pharmaceuticals

Rx Wholesalers Responding To Subpoenas On Deals With “Secondary” Market

AmerisourceBergen, Cardinal Health and McKesson are responding to subpoenas from the New York Attorney General's office regarding their use of "secondary" wholesalers as a source of pharmaceuticals

GSK Wellbutrin XL Launch Not Affected By Lost Shipment, Biovail Says

GlaxoSmithKline's ongoing launch of Wellbutrin XL will not be affected by the loss of a product shipment from Biovail's manufacturing facility, Biovail assured analysts during an Oct. 3 teleconference

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel